<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02061813</url>
  </required_header>
  <id_info>
    <org_study_id>Ha03-007</org_study_id>
    <nct_id>NCT02061813</nct_id>
  </id_info>
  <brief_title>Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion</brief_title>
  <official_title>A 21-Day, Randomized, Controlled Study to Evaluate the Irritation Potential of Abametapir Lotion in Healthy Volunteers, Using a Cumulative Irritant Patch Test Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the irritation potential of repeat applications of&#xD;
      abametapir lotion on normal skin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, evaluator-blind, single-center, controlled, within-subject&#xD;
      comparison study of the investigational products (abametapir lotion) and its vehicle lotion&#xD;
      and positive and negative controls under occlusive conditions in healthy volunteers. All&#xD;
      subjects will have the investigational product (abametapir lotion), the vehicle product, the&#xD;
      positive control patch, and negative control patch applied to 4 randomly assigned, adjacent&#xD;
      skin sites on the infrascapular area of their back, for the purpose of determining irritation&#xD;
      potential.&#xD;
&#xD;
      The investigational products, vehicle, and controls will be applied to one side of the&#xD;
      infrascapular area of the back. Evaluation of dermal reactions at the application sites will&#xD;
      be assessed clinically using a visual scale that rates the degree of erythema, edema, and&#xD;
      other signs of cutaneous irritation (see Section 3.5.5).&#xD;
&#xD;
      A total of 21 applications of each product will be made.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Potential of Abametapir Lotion to Cause Irritation After Repeated Topical Application to the Healthy Skin of Humans.</measure>
    <time_frame>21 days</time_frame>
    <description>The evaluation of irritation is based on Modified Berger procedure and is accepted as standard methodology for assessment of cumulative irritation potential. The assessment of all patch sites for irritation symptoms will be visually assessed by a trained evaluator using the numerical equivalents (0-7) where 0 is the least irritation potential and 7 is the maximum irritation potential. The scoring will be done on daily basis from baseline through Day 21 visit. The final reported outcome is a mean of the scores over 21 days.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Head Lice</condition>
  <arm_group>
    <arm_group_label>Abametapir lotion 0.74% w/w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applied 0.2 mL topically under occlusive condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle lotion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Applied 0.2 mL topically under occlusive condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Lauryl Sulfate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Positive control applied 0.2 mL topically under occlusive condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline 0.9%</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Negative control applied 0.2 mL topically under occlusive condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abametapir Lotion 0.74% w/w</intervention_name>
    <description>applied 0.2 mL topically under occlusive condition</description>
    <arm_group_label>Abametapir lotion 0.74% w/w</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Lauryl Sulfate</intervention_name>
    <description>Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.</description>
    <arm_group_label>Sodium Lauryl Sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 0.9%</intervention_name>
    <description>A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control</description>
    <arm_group_label>Saline 0.9%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Vehicle lotion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Are healthy (to be confirmed by medical history) males or females, 18 years of age or&#xD;
             older;&#xD;
&#xD;
          2. In the case of females of childbearing potential, are using an acceptable form of&#xD;
             birth control (oral/implant/injectable/transdermal contraceptives, intrauterine&#xD;
             device, condom with spermicide, diaphragm with spermicide, abstinence, partner's&#xD;
             vasectomy). Abstinence or vasectomized partner are acceptable if the female subject&#xD;
             agrees to implement one of the other acceptable methods of birth control if her&#xD;
             lifestyle/partner changes;&#xD;
&#xD;
          3. If female of childbearing potential, have a negative urine pregnancy test (UPT) at Day&#xD;
             1, and are willing to submit to a pregnancy test at the end of study (EOS);&#xD;
&#xD;
          4. Are free of any systemic or dermatologic disorder, which, in the opinion of the&#xD;
             investigator, will interfere with the study results or increase the risk of adverse&#xD;
             events;&#xD;
&#xD;
          5. Are of any skin type or race, providing the skin pigmentation will allow discernment&#xD;
             of erythema;&#xD;
&#xD;
          6. Complete a patch study Medical Screening form as well as a Medical Personal History&#xD;
             form; and&#xD;
&#xD;
          7. Read, understand, and provide signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have any visible skin disease at the application site which, in the opinion of the&#xD;
             investigative personnel, will interfere with the evaluation of the test site reaction;&#xD;
&#xD;
          2. Are not willing to refrain from using topical/systemic analgesics such as aspirin&#xD;
             (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72&#xD;
             hours prior to and during the study (occasional use of acetaminophen will be&#xD;
             permitted);&#xD;
&#xD;
          3. Are using inhaled/systemic/topical corticosteroids in the 3 weeks prior to and during&#xD;
             the study, or systemic/topical antihistamines for 72 hours prior to and during the&#xD;
             study;&#xD;
&#xD;
          4. Are using medication which, in the opinion of the investigative personnel, will&#xD;
             interfere with the study results, including anti-inflammatory medications;&#xD;
&#xD;
          5. Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams,&#xD;
             ointments, lotions, or similar products on the back during the study;&#xD;
&#xD;
          6. Have psoriasis and/or active atopic dermatitis/eczema;&#xD;
&#xD;
          7. Are females who are pregnant, plan to become pregnant during the study, or are&#xD;
             breast-feeding a child;&#xD;
&#xD;
          8. Have a known sensitivity to constituents present in the material being evaluated;&#xD;
&#xD;
          9. Have damaged skin in or around the test sites, including sunburn, excessively deep&#xD;
             tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other&#xD;
             disfigurations of the test site&#xD;
&#xD;
         10. Have received treatment for any type of internal cancer within 5 years prior to study&#xD;
             entry;&#xD;
&#xD;
         11. Have a history of, or are currently being treated for skin cancer;&#xD;
&#xD;
         12. Are currently participating in any other clinical trial,&#xD;
&#xD;
         13. Have any known sensitivity to adhesives; and/or&#xD;
&#xD;
         14. Have received any investigational treatment(s) within 4 weeks prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Dosik</last_name>
    <role>Principal Investigator</role>
    <affiliation>TKL Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TKL Reserach Inc</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 7, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2014</study_first_posted>
  <results_first_submitted>May 15, 2021</results_first_submitted>
  <results_first_submitted_qc>July 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2021</results_first_posted>
  <last_update_submitted>July 3, 2021</last_update_submitted>
  <last_update_submitted_qc>July 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hatchtech</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Randomized Subjects</title>
          <description>All Randomized Subjects included all subjects who were enrolled into the study. All subjects had the investigational product (abametapir lotion), the vehicle product, the positive control patch, and negative control patch applied to 4 randomly assigned, adjacent skin sites on the infrascapular area of their back, for the purpose of determining irritation potential.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Abametapir Lotion</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vehicle Lotion</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Saline 0.9%</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>SLS 0.2%</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Randomized Subjects</title>
          <description>All Randomized Subjects included all subjects who were enrolled into the study. All subjects had the investigational product (abametapir lotion), the vehicle product, the positive control patch, and negative control patch applied to 4 randomly assigned, adjacent skin sites on the infrascapular area of their back, for the purpose of determining irritation potential.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.95" spread="14.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type</title>
          <description>The Fitzpatrick (FP) Scale is a numerical classification schema for human skin color. FP 1 is for white skin type and progressively becoming darker until FP 6 which is for black skin type.&#xD;
FP 1 = Always burns easily, never tans; FP 2 = Always burns easily, tans minimally; FP 3 = Burns moderately, tans gradually (light brown); FP 4 = Burns minimally, always tans well (moderate brown); FP 5 = Rarely burns, tans very well (moderate brown); FP 6 = Never burns, deeply pigmented</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Fitzpatrick Type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fitzpatrick Type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fitzpatrick Type 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fitzpatrick Type 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fitzpatrick Type 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Potential of Abametapir Lotion to Cause Irritation After Repeated Topical Application to the Healthy Skin of Humans.</title>
        <description>The evaluation of irritation is based on Modified Berger procedure and is accepted as standard methodology for assessment of cumulative irritation potential. The assessment of all patch sites for irritation symptoms will be visually assessed by a trained evaluator using the numerical equivalents (0-7) where 0 is the least irritation potential and 7 is the maximum irritation potential. The scoring will be done on daily basis from baseline through Day 21 visit. The final reported outcome is a mean of the scores over 21 days.</description>
        <time_frame>21 days</time_frame>
        <population>All Randomized Subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Abametapir Lotion Group</title>
            <description>All Subjects in the study received all treatments simultaneously on a daily basis, as it was an intra-subject comparison design</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Lotion</title>
            <description>All Subjects in the study received all treatments simultaneously on a daily basis, as it was an intra-subject comparison design</description>
          </group>
          <group group_id="O3">
            <title>Saline 0.9%</title>
            <description>All Subjects in the study received all treatments simultaneously on a daily basis, as it was an intra-subject comparison design</description>
          </group>
          <group group_id="O4">
            <title>Sodium Lauryl Sulphate (SLS)</title>
            <description>All Subjects in the study received all treatments simultaneously on a daily basis, as it was an intra-subject comparison design</description>
          </group>
        </group_list>
        <measure>
          <title>Potential of Abametapir Lotion to Cause Irritation After Repeated Topical Application to the Healthy Skin of Humans.</title>
          <description>The evaluation of irritation is based on Modified Berger procedure and is accepted as standard methodology for assessment of cumulative irritation potential. The assessment of all patch sites for irritation symptoms will be visually assessed by a trained evaluator using the numerical equivalents (0-7) where 0 is the least irritation potential and 7 is the maximum irritation potential. The scoring will be done on daily basis from baseline through Day 21 visit. The final reported outcome is a mean of the scores over 21 days.</description>
          <population>All Randomized Subjects</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Skin Sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Skin Sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="3.11"/>
                    <measurement group_id="O2" value="0.70" spread="2.89"/>
                    <measurement group_id="O3" value="1.10" spread="6.48"/>
                    <measurement group_id="O4" value="49.15" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse events were systematically recorded from the time of signing informed consent until the last assessment i.e. 21 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Randomized Subjects</title>
          <description>All Randomized Subjects included all subjects who were enrolled into the study. All subjects received application of all four interventions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Srinivas Sidgiddi</name_or_title>
      <organization>Dr. Reddy's Laboratories Inc.</organization>
      <phone>9084585362</phone>
      <email>srinivassidgiddi@drreddys.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

